Company intelligence / Profile preview

Cambridge Vision Technology

Bern, Switzerland

Ownership: Private
Development stage: Other

Overview

Cambridge Vision Technology has demonstrated that its retinal imaging and AI-based diagnostic platform can non-invasively detect early risk of Alzheimer's disease and mild cognitive impairment; successful trials have been conducted with academic partners and a contract was secured to deliver its solution after accelerator program graduation[7].

Therapeutic areas: Neurology
Modalities: DeviceSoftwareDiagnostic test
Industry: Medical Imaging

Partnerships

University of CambridgeUK government (contract recipient)[7]

Beyond the preview

Go deeper on Cambridge Vision Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambridge Vision Technology.

Explore the full profile